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Background: Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is
a severe complication associated with a high mortality. However, evidence
and guidance on management is sparse. The aim of this international
survey was to assess differences in prevention, diagnostic and treatment
strategies for AE-IPF in specialised and non-specialised ILD centres worldwide.
Polke et al. Differences of AE-IPF Management
Material and Methods: Pulmonologists working in specialised and non-specialised
ILD centres were invited to participate in a survey designed by an international expert
panel. Responses were evaluated in respect to the physicians’ institutions.
Results: Three hundred and two (65%) of the respondents worked in a specialised ILD
centre, 134 (29%) in a non-specialised pulmonology centre. Similarities were frequent
with regards to diagnostic methods including radiology and screening for infection,
treatment with corticosteroids, use of high-flow oxygen and non-invasive ventilation
in critical ill patients and palliative strategies. However, differences were significant in
terms of the use of KL-6 and pathogen testing in urine, treatments with cyclosporine
and recombinant thrombomodulin, extracorporeal membrane oxygenation in critical ill
patients as well as antacidmedication and anaesthesia measures as preventivemethods.
Conclusion: Despite the absence of recommendations, approaches to the prevention,
diagnosis and treatment of AE-IPF are comparable in specialised and non-specialised
ILD centres, yet certain differences in the managements of AE-IPF exist. Clinical trials
and guidelines are needed to improve patient care and prognosis in AE-IPF.
Keywords: idiopathic pulmonary fibrosis, acute exacerbation, questionnaire, pulmonologists, specialised ILD
centres, non-specialised ILD centres
INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive
fibrosing interstitial lung disease associated with a poor prognosis
with a five-year survival rate of 20–40% and a median survival
time of 2–5 years (1, 2). An acute exacerbation of IPF
contributes to the dismal prognosis and disease progression
and is defined as an acute, clinically significant respiratory
deterioration characterised by evidence of new widespread
alveolar abnormality in patients with IPF and after the exclusion
of cardiac failure or fluid overload (3). The annual incidence
is up to 20%, depending on the population analysed (4,
5). AE-IPF is associated with a median survival of ∼3–
4 months (6, 7) and may account for more than 40% of
all death in patients with IPF (8). The aetiology is still
obscure, but AE-IPF might be triggered e.g. by infection or
procedures/operation, or may occur idiopathic (6). Evidence
on prevention, diagnosis and therapy of AE-IPF is sparse
and no international guidelines exist (3, 9). Accordingly, there
is a huge variability with regards to preventive, diagnostic
and therapeutic approaches worldwide (10). It is unknown
whether these different strategies are partially explainable by
differences between specialised and non-specialised ILD centres.
Therefore, this study aimed to compare preventive, diagnostic
and therapeutic strategies for AE-IPF between specialised and
non-specialised ILD centres.
MATERIALS AND METHODS
Questionnaire and Participating Physicians
As described previously (10), as a first step we conducted a
literature research on diagnostics, therapy, prevention and
management of AE-IPF to identify items to be included in
this survey. Then, an expert panel was created, comprising
pulmonologists with expertise in the diagnosis and management
of ILD working in specialist ILD centres and a track
record of publication in this field, to participate in an
email-based interview to structure the survey. The final
questionnaire consisted of 20 questions regarding diagnosis,
treatment and prevention of AE-IPF and suggested future
perspectives in AE-IPF research (10). To identify working
place (specialised and non-specialised ILD centres), country
of origin, number of patients with IPF under care, and
estimated number of AE-IPF seen, additional questions were
included into this survey. From July 1 2017 to November
30 2017 pulmonologists worldwide with interest in ILD
were identified, including the European Respiratory Society
assembly on Diffuse Parenchymal Lung Disease, the American
Thoracic Society assembly on Clinical Problems, the Japanese
Respiratory Society assembly on Diffuse Parenchymal Lung
Disease and participants of the IPF Project Consortium
(www.theipfproject.com) (11). Nationality, academic status
(working at a university hospital or not) or subspecialist
interests within respiratory medicine did not influence
inclusion eligibility. The questionnaire was provided by the
online survey tool SurveyMonkey R© from December 2017 to
April 2018.
Statistical Analysis
For questions with categorical answers, absolute and relative
frequencies were calculated and chi-squared tests were used
to assess differences between specialised and non-specialised
ILD centres. For questions with answers on a continuous
scale, median, first and third quartile, minimum and maximum
were determined and differences between continents were
assessed using Kruskal–Wallis tests. Due to the exploratory
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nature of this survey, all resulting p-values are solely to be
interpreted descriptively and no adjustment for multiple testing
was conducted. p-values smaller than 0.05 were regarded as




Overall, 509 pulmonologists from 66 countries responded. Three
hundred and thirty four (65.9%) of the participants worked in
a specialised ILD centre, 142 (28.0%) in non-specialised ILD
centres i.e. in a general pulmonology department, 4 (0.8%) on
an intensive care unit and 27 (5.3%) did not indicate their
institution. Physicians working on an intensive care unit or who
did not indicate their institution were excluded from the analysis.
A total of 436 pulmonologists working in a specialised or non-
specialised ILD centre were included in this analysis. On average
331 cases of AE-IPF were seen in specialised ILD centres and 139
in non-specialised ILD centres. Figure 1 shows the place of work
(continent) of the respondents in specialised and non-specialised
ILD centres.
Diagnostic Procedures for AE-IPF
Most diagnostic tools, including multi-slice thin-section
computer tomography without contrast media (HRCT), CT with
contrast media in the absence of clinical suspicion of pulmonary
embolism, bronchoalveolar lavage (BAL), echocardiography,
assessment for pathogens, NT-proBNP/BNP, D-Dimer and
troponins were used similarly between specialised and non-
specialised ILD centres. The main difference was the sampling
of sputum for microbiology (induced sputum) which was
more frequent in non-specialised ILD centres (22 vs. 12%, p =
0.0106). Conversely, pathogen testing in urine was performed
significantly more often in specialised ILD centres than in
non-specialised ILD centres (42 vs. 28%, p = 0.0068). 50% of
specialised ILD centres screened for RSV (respiratory syncytial
virus), compared to only 33% in non-specialised ILD centres
(p = 0.0024). The use of biomarker KL-6 was higher in non-
specialised ILD centres than in specialised ILD centres (24 vs.
15%, p = 0.0313). The most relevant diagnostic procedures
applied for AE-IPF are shown in Figure 2. Other diagnostic
procedures such as laboratory parameters or specific pathogens
are shown in Supplementary 1.
Treatment Approaches for AE-IPF
The majority of participating pulmonologists treated AE-IPF
with methylprednisolone or equivalent with a dosage of 500–
1,000mg per day for 3 days followed by a slow tapering similarly
in both types of institutions (63 vs. 66%).
Other immunosuppressive therapies such as cyclosporine,
cyclophosphamide (i.v. bolus), tacrolimus and rituximab were
rarely used in both specialised and non-specialised ILD centres,
but cyclosporine was significantly more frequently used in non-
specialised ILD centres (13 vs. 6%, p= 0.0288).
Other therapies such as polymyxin B hemoperfusion (7 vs.
10%), and plasmapheresis/plasma exchange (4 vs. 5%) were
also less commonly used in specialised and non-specialised ILD
centres. However, significantlymore pulmonologists treated their
patients with recombinant thrombomodulin in non-specialised
ILD centres than in specialised ILD centres (15 vs. 8%, p
= 0.0342).
Differences between institutions in the use of treatment
strategies are shown in Figure 3. See also Supplementary 1.
FIGURE 1 | Number of participants in specialised and non-specialised ILD centres from different continents.
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Antifibrotic Therapy Management During
AE-IPF
In patients without antifibrotic therapy, the majority of the
survey participants see a reason to initiate an antifibrotic therapy
in the event of an AE-IPF in specialised and non-specialised ILD
centres (66 vs. 69%).
The choice of the antifibrotic drug did also not differ
significantly between specialised and non-specialised centres
(nintedanib 20 vs. 20%, pirfenidone 11 vs. 19%, no preference for
specific anti-fibrotic drug 35 vs. 28%).
For patients already on antifibrotic therapy at the time of AE-
IPF, there was no significant difference in the approach: 80%
of respondents in specialised ILD centres would continue and
5% would discontinue antifibrotic therapy, compared to 70%
continuing (p = 0.0513) and 7% discontinuing therapy (p =
0.5491) in non-specialised ILD centres. The dose was reduced by
1 % in specialised ILD centres compared to 5% in non-specialised
ILD centres (p = 0.0301), 9% would switch to the alternative
antifibrotic therapy in specialist ILD centres and similarly 10%
would switch in non-specialised ILD centres (p= 0.999).
Different strategies in this situation are also shown in Figure 4.
For further strategies see Supplementary 1.
Management of Pulmonary Hypertension
(PH) During AE-IPF
In the case of suspected PH on clinical investigations (e.g.
echocardiography, BNP, clinical signs) during an AE-IPF,
significantly more physicians in specialised ILD centres would
start diuretic therapy than in non-specialised ILD centre (54 vs.
41%, p = 0.0210). Only a minority in both institutions would
perform right heart catheterization in AE-IPF in suspected PH
(6 vs. 7%). Seven percentage would start a PH specific treatment
after an established PH diagnosis in a specialised ILD centre,
significantly more (14%) would do so in a non-specialised ILD
centre (p = 0.0494). Only 3% of physicians in a specialised
ILD centre and 1% in a non-specialised centre would start
a PH specific treatment without a confident diagnosis. After
stabilisation of AE-IPF, more than 50% of physicians would
evaluate a PH specific treatment by subsequently performing
right heart catheterization (56 vs. 55%). A quarter of all
participating pulmonologists in specialised and non-specialised
ILD centres saw no indication for a PH treatment during or after
AE-IPF (Supplementary 1).
Intensive Care Unit (ICU) and Palliative
Care in AE-IPF
With regards to the care for critically ill patients with AE,
there were no differences in specialised and non-specialised
ILD centres for the use of high-flow oxygen (84 vs. 78%) and
non-invasive ventilation (NIV) (72 vs. 77%). 9% of specialised
and 11% of non-specialised ILD centres use invasive ventilation
for all critical ill patients, whereas 48 vs. 39% respectively
would only use invasive ventilation in patients suitable for lung
transplantation (LTX) as a bridge to LTX or in very selected cases.
FIGURE 2 | The main diagnostic procedures applied for AE-IPF in specialised and non-specialised ILD centres. Statistically significant differences are labelled with a *
(p-value = <0.05).
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FIGURE 3 | Different treatment strategies towards AE-IPF in specialised and non-specialised ILD centres. Statistically significant differences are labelled with a *
(p-value = <0.05).
FIGURE 4 | Different strategies in AE-IPF concerning an antifibrotic treatment in specialised and non-specialised ILD centres. Statistically significant differences are
labelled with a * (p-value = <0.05).
Significantly more physicians in specialised ILD centres
offered extracorporeal membrane oxygenation (ECMO) to
patients suitable for LTX as a bridge to LTX than in non-
specialised ILD centres (49 vs. 36%, p= 0.0287).
Palliative care was considered similarly in both types of
institutions (65 vs. 62%).
Institutional differences in these approaches are shown in
Figure 5 (Supplementary 1).
Preventive Strategies for AE-IPF
Measures aimed at preventing the occurrence of AE-IPF was
equal amongst specialised and non-specialised ILD centres
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FIGURE 5 | Different management strategies in critically ill patients with AE-IPF in specialised and non-specialised ILD centres. Statistically significant differences are
labelled with a * (p-value = <0.05).
and included vaccinations, antifibrotic therapy and pulmonary
rehabilitation or other forms of structured exercise therapy.
Antacid drugs were prescribed significantly more in non-
specialised ILD centres than in specialised ILD centres (61 vs.
50%, p = 0.0438) in all IPF patients. Long-term azithromycin,
low dose steroids (≤10mg) and anticoagulation (to prevent
AE-IPF) were only used by a minority in both types
of institutions.
In terms of planned surgical procedures, significantly more
physicians in specialised ILD centres favoured preventive
anaesthetic measures such as low tidal volume and avoidance
of hyperoxygenation compared to physicians in non-specialised
ILD centres (72 vs. 61%, p=0.0368).
Institutional differences in preventive strategies are shown in
Figure 6. See also Supplementary 1.
Unmet Needs in AE-IPF
Pulmonologists in both specialised and non-specialised ILD
centres advocate more intensive collaboration between different
ILD specialists; improved education and training of physicians;
education of patients and caregivers as well as enhanced research
to improve the understanding of the pathophysiology, diagnosis
and management of AE-IPF. Physicians working in specialised
ILD centres saw a stronger need for intensified research and
projects on the treatment of AE-IPF (90 vs. 80%, p = 0.0101).
There were more pulmonologists in non-specialised ILD centres
who saw a need of improvement in multidisciplinary strategies
for diagnosing and discussions than in specialised ILD centres
(67 vs. 53%, p= 0.0088).
DISCUSSION
Despite the fact that AE-IPF is one of the most common causes
of death in IPF (3), evidence on prevention, additional diagnostic
approaches besides HRCT and treatment of this complication
is sparse and differs significantly worldwide (10). No particular
evidence-based guidance exists. Here we report analyses on
similarities and differences in the management of AE-IPF in
specialised vs. non-specialised ILD centres. The strength of our
report was the significant number of physicians who replied
to our survey representing both specialised and non-specialised
ILD centres.
Diagnostic procedures were almost identical in both
specialised and non-specialised ILD centres, including radiology
and screening for infections. Molyneaux et al. have showed that
there is an increased bacterial load in the BAL of IPF patients
with AE-IPF compared to stable IPF patients (12) suggesting
a potential causative role in AE-IPF. There is evidence for the
contribution of lung microbiota in disease progression and in
acute exacerbation (13, 14). Microbiological confirmation may
therefore play an important role in the diagnostic process and
may be useful for future therapeutic and preventive strategies.
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FIGURE 6 | Different preventive strategies in AE-IPF in specialised and non-specialised ILD centres. Statistically significant differences are labelled with a * (p-value =
<0.05).
The majority of physicians in specialised and non-specialised
ILD centres screen for pathogens in sputum, deemed a safer
method to screen for pathogens compared to bronchoscopy. A
recent study supports this approach as a positive bronchoscopy
only affected management in 13% of patients and resulted in
a change of treatment in <5% (15). Furthermore, in the same
study, a significant number of patients required intubation
and transfer to the ICU with poor extubation success post
bronchoscopy (15). Conversely, a study has demonstrated
the feasibility and safety of performing BAL aided by NIV
as a useful tool for differentiating or confirming triggered
AE (16).
Furthermore, there is a similarity in therapeutic approaches.
The majority of pulmonologists in specialised and non-
specialised ILD centres use antibiotic therapy, namely broad-
spectrum antibiotic combinedwithmacrolide. High dose steroids
are widely administered in non-specialised and specialised
ILD centres in AE-IPF. High dose long-term steroid use was
associated with an increasedmortality in the PANTHER trial (17)
and a history of previous immunosuppression before AE-IPF has
a negative impact on mortality (18). Recently, a retrospective
study with 82 AE-IPF patients showed that subjects receiving
corticosteroids were more likely to require ICU level care
and mechanical ventilation and therefore did not benefit from
treatment with corticosteroids (19). However, future studies with
larger cohorts are necessary to prove the deleterious effects of
steroid therapy.
Other immunosuppressants and strategies are used
less frequently. Very few pulmonologists never use
immunosuppression for AE-IPF. Although there is only
low evidence base for the use of more potent anti-inflammatory
treatment approaches such as cyclosporine A, intravenous
cyclophosphamide or tacrolimus (20–24), they are used by some
pulmonologists in non-specialised and specialised ILD centres. A
randomised, double-blinded clinical trial of cyclophosphamide in
AE-IPF with 120 patients was completed and results are eagerly
awaited (https://clinicaltrials.gov/ct2/show/NCT02460588).
The international guidelines recommend avoiding ICU in
patients with AE-IPF (weak recommendation) (25) because the
mortality of patients with AE-IPF admitted to ICU, particularly
in ventilated patients, is high (26). Some patients who do not
respond to conventional oxygen therapy benefit from high flow
oxygen (27). NIV may be a reasonable option for some critically
ill patients (28). Trudzinski et al. showed that ECMO is only
an option for patients who are suitable for LTX, as it conferred
limited impact on the poor prognosis for those who were not
LTX candidates (29). This might be a reason for pulmonologists
in nomatter what kind of institution to prefer NIV and high-flow
oxygen in patients with AE-IPF. Data on this is however limited.
In non-specialised and specialised ILD centres prevention
strategies towards AE-IPF were performed to the same extent.
Vaccinations were most frequently used; although their use is
recommended by the international guideline, there is a lack of
evidence to support this recommendation (30).
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The approach by physicians to utilise antifibrotic drugs as
a form of preventive strategy is supported by recent data
of controlled trials that suggest nintedanib may prolong the
time to the first AE-IPF (31) and reduces mortality after AE-
IPF (32). Pirfenidone reduces the risk for respiratory related
hospitalisation in post-hoc analyses (33). Data proving a reduced
frequency of AE-IPF with pirfenidone is sparse: In a Phase 2 trial
of 107 patients Azuma et al. found a significant reduction of AE-
IPF in patients using pirfenidone (34). A larger trial could not
prove this (35).
While a Japanese study suggested a role for anticoagulants
to prevent AE-IPF (Kubo et al.), a more recent study did not
support this (36). This is in line with the results shown here: only
a minority use anticoagulants to prevent AE-IPF. This is further
supported by data suggesting a negative impact of anticoagulants
on survival in IPF in general (37, 38).
Besides many similarities in the approach towards AE-IPF,
there are also some differences in ILD specialised and non-
specialised ILD centres.
PH is common in patients with IPF (39). Its prevalence at
baseline means a higher risk for a subsequent AE-IPF, it is
associated with a poorer overall survival but until now no specific
PH treatment could show a benefit for IPF patients (40, 41).
Significantly more pulmonologists in specialised ILD centres
start diuretics compared to non-specialised ILD centres, and in
line with the lack of benefits for specific PH treatment, most
physicians do not use a specific PH treatment.
Many physicians use antacid drugs as a preventive strategy
for AE-IPF, significantly more in non-specialised ILD centres.
Lee et al. reported a higher pepsin level in the BAL of patients
with AE-IPF compared to patients with stable disease (42) and a
retrospective analysis showed a positive impact of antacid drugs
on the course of IPF (43, 44). Other studies could not repeat
this effect and suggested potentially higher rates of respiratory
infections (45) and AE-IPF (46). The reason for the difference
in the use of anti-acid drugs remains unclear, maybe because
specialised ILD centres treat patients who are more ill or
receive palliative treatment. Also different prescription rules in
different countries or the fact that an old statement published by
international societies from 2011 recommended their use (9) may
be responsible.
Only a few pulmonologists use low dose steroids as a
preventive strategy for AE-IPF, most of them in non-specialised
ILD centres. This approach is in line with the international
guideline where it is not recommended to use steroids beyond
AE-IPF (17, 25). Furthermore, the use of corticosteroids has a
negative effect on the outcome of IPF patients who received
nintedanib (47).
Both pulmonologists in specialised and non-specialised ILD
centres saw a high requirement for improved research strategies
for AE-IPF. Significantly more non-specialised ILD centres
saw the need for improvement in multidisciplinary strategies
for diagnosing and discussion compared to pulmonologists
in specialised ILD centres. Multidisciplinary team (MTD)
meetings are widely used in the process of diagnostic and
patient management (48) and they improve confidence in ILD
diagnostics (49). MTDmeetings are officially recommended (50).
Arguably, MTD are more available in specialised ILD centres.
Many of the differences observed underscore the high and
still unmet need for intensive research in AE-IPF. However,
others might be associated with strategies applied outside current
evidence. This demonstrates how important education in rare
diseases and their complications is.
Our survey has some limitations: The survey was not designed
for a data driven assessment of management practises but
mainly to evaluate attitudes towards different aspects of AE-
IPF. Participation was voluntarily and biased by involvement
i.e. non-participating centres may have answered differently.
Additionally, there was an imbalance between the number
of specialised and non-specialised ILD institutions. Moreover,
the number of ILD centres and patient numbers and thus
experiences of diagnosis and management of AE-IPF may vary
from country to country. Arguably, the number of IPF patients
and cases of AE-IPF are higher in Japan as an example, than
in other countries (51). Therefore, non-specialised ILD centres
in Japan may have a higher number of patients to treat and
thus greater experience than other non-specialised ILD centres
elsewhere. More experienced physicians in the field of AE-
IPF might have influenced the results of this questionnaire.
Furthermore, the availability of treatments differs clearly between
countries/continents, e.g., recombinant thrombomodelin is used
almost exclusively in Asia and here by a quarter of all physicians
(10). This might explain the fact that thrombomodulin is used
more often in non-specialised ILD centres. The same applies for
the use of KL-6 in the diagnostic process of AE-IPF. Finally, not
all aspects of approaches to AE-IPF could be addressed in the
questionnaire. The current COVID-19 pandemic was not part of
the questionnaire because it was sent out before. This situation
might have a huge impact on how AE-IPF is managed and this
was not assed in the survey.
In conclusion, specialised and non-specialised ILD centres
throughout the world do only differ in some aspects in
the management of AE-IPF. Due to scant evidence and
missing focused guidelines basic research and clinical trials
have to be performed to establish optimal approaches to this
deadly complication.
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